BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
June 2, 2020
View Archived Issues
FDA clears IND application for first-in-human trial of IO-202
Read More
FDA approves Tauvid for PET imaging in patients being evaluated for AD
Read More
Phenotype detection platform screens for new PD drugs
Read More
Tumor types have distinct microbiomes
Read More
New alcohol risk genes in Caucasians
Read More
A series of benzimidazolones causing rapid degradation of BCL6 as potential therapeutics for DLBCL
Read More
New inhibitors of the minichromosomal maintenance protein with potential for the treatment of NSCLC
Read More
LMP2 inhibition shows therapeutic potential in AD by protecting against neuroinflammation
Read More
Edgewise Therapeutics presents new myosin inhibitors
Read More
New JAK-2 inhibitors identified at the Dana-Farber Cancer Institute
Read More
Rudong Ringene Pharmaceuticals patents PTPN11 inhibitors
Read More
New histone deacetylase inhibitors discovered at Merck & Co.
Read More
Genentech and Roche synthesize new RAS protein inhibitors
Read More
Novus reports topline phase IIa data on OP-0201 in acute otitis media
Read More
Gilead reports phase III data on remdesivir in moderate COVID-19 pneumonia
Read More
FDA clears Opko to begin phase II trial of Rayaldee for mild to moderate COVID-19
Read More
Ocugen discontinues phase III trial of OCU-300 for ocular graft-versus-host disease
Read More
Interim phase Ib data with ALRN-6924 show chemoprotective effect
Read More
Avelumab does not show activity in recurrent osteosarcoma trial
Read More
FDA approves Brilinta to reduce first heart attack in patients with coronary artery disease
Read More
Mesothelin-targeting CAR MCY-M11 appears to be safe in phase I trial
Read More
Nicox's NCX-470 enters phase III development
Read More
CTI enrolling patients in phase III PREVENT trial of pacritinib in severe COVID-19
Read More
Olokizumab obtains first approval in Russia
Read More
Phase III study of sulopenem in cUTI does not meet primary endpoint
Read More
FDA approves Taltz for active nonradiographic axial spondyloarthritis
Read More